USPTO ignites CRISPR/Cas9 patent battle

Scientists from two US universities will fight out the ownership of the intellectual property rights to the CRISPR/Cas9 technology after the US Patent and Trademark Office (USPTO) agreed to initiate an interference proceeding.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Let CRISPR/Cas9 battle commence

11 March 2016 The US Patent and Trademark Office has opened proceedings to determine who owns the rights to the CRISPR/Cas9 technology.

Americas

Editas goes public amid CRISPR patent battle

10 February 2016 A biotechnology company that licenses a patent related to the gene-editing technology CRISPR/Cas9 has raised more than $94 million in its initial share offering.

Big Pharma

CRISPR: the shifting sands of patentability

12 November 2015 The patentability of any claims directed to the use of CRISPR technology in human embryo-like structures and human reproductive cells is far from certain, as Duncan Ribbons and Maeve Lynch of Redd explain.

More on this story

Americas

Let CRISPR/Cas9 battle commence

11 March 2016 The US Patent and Trademark Office has opened proceedings to determine who owns the rights to the CRISPR/Cas9 technology.

Americas

Editas goes public amid CRISPR patent battle

10 February 2016 A biotechnology company that licenses a patent related to the gene-editing technology CRISPR/Cas9 has raised more than $94 million in its initial share offering.

Big Pharma

CRISPR: the shifting sands of patentability

More on this story

Americas

Let CRISPR/Cas9 battle commence

11 March 2016 The US Patent and Trademark Office has opened proceedings to determine who owns the rights to the CRISPR/Cas9 technology.

Americas

Editas goes public amid CRISPR patent battle

10 February 2016 A biotechnology company that licenses a patent related to the gene-editing technology CRISPR/Cas9 has raised more than $94 million in its initial share offering.

Big Pharma

CRISPR: the shifting sands of patentability